Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;100(6):1337-1340.
doi: 10.1016/j.kint.2021.09.014. Epub 2021 Oct 4.

Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients

Dominique Bertrand  1 , Mouad Hamzaoui  2 , Veronique Lemée  3 , Julie Lamulle  4 , Charlotte Laurent  2 , Isabelle Etienne  2 , Mathilde Lemoine  2 , Ludivine Lebourg  2 , Mélanie Hanoy  2 , Frank Le Roy  2 , Dorian Nezam  2 , Fabienne Farce  5 , Jean-Christophe Plantier  3 , Olivier Boyer  6 , Dominique Guerrot  2 , Sophie Candon  6
Affiliations

Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients

Dominique Bertrand et al. Kidney Int. 2021 Dec.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike (S) antibody response in kidney transplant recipients (KTRs) following a second and third injection of SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer–BioNTech). Median and interquartile range for anti–S IgG antibody titers are shown. The threshold for antibody positivity is 50 arbitrary units (AUs)/ml. (a) S IgG antibody titers in all 80 KTRs. (b) S IgG titers in the 30 KTRs who were seropositive after the second dose. (c) S IgG titers in the 50 KTRs who were seronegative after the second dose.
Figure 2
Figure 2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–reactive interferon-γ–producing T cells in kidney transplant recipients (KTRs) following the second and third injection of the SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer–BioNTech). (a) Total numbers of T cells (expressed as spot-forming cells [SFCs]/106 CD3+ T cells) reactive to overlapping peptide pools spanning the SARS-CoV-2 structural spike protein S (pools S1 and S2) in all 80 KTRs. Median and interquartile range are shown. (b) T-cell response in the 40 KTRs showing significant anti-spike T-cell numbers after the second dose. (c) T-cell response in the 40 KTRs without a significant T-cell response after the second dose (cutoffs for significant T-cell numbers were 25 and 40 SFCs/106 CD3+ T cells for pools S1 and S2, respectively).
See this image and copyright information in PMC

References

    1. Bertrand D., Hamzaoui M., Lemée V., et al. Antibody and T cell response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and hemodialysis patients. J Am Soc Nephrol. 2021;32:2147–2152. - PMC - PubMed
    1. Caillard S., Chavarot N., Bertrand D., et al. Occurrence of severe COVID-19 in vaccinated transplant patients. Kidney Int. 2021;100:477–479. - PMC - PubMed
    1. Kamar N., Abravanel F., Marion O., et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385:661–662. - PMC - PubMed
    1. Hall V.G., Ferreira V.H., Ku T., et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385:1244–1246. - PMC - PubMed